# üèÜ TOP 5 –û–¢–ö–†–´–¢–ò–ô ECM-ATLAS
## –ö—Ä–∞—Ç–∫–∞—è —Å–≤–æ–¥–∫–∞ –ø–∞—Ä–∞–ª–ª–µ–ª—å–Ω–æ–≥–æ –∞–Ω–∞–ª–∏–∑–∞ 5 –∞–≥–µ–Ω—Ç–æ–≤

**–î–∞—Ç–∞:** 15 –æ–∫—Ç—è–±—Ä—è 2025
**–î–∞—Ç–∞—Å–µ—Ç:** 9,343 –∏–∑–º–µ—Ä–µ–Ω–∏–π √ó 13 –∏—Å—Å–ª–µ–¥–æ–≤–∞–Ω–∏–π √ó 17 —Ç–∫–∞–Ω–µ–π

---

## ü•á –û–¢–ö–†–´–¢–ò–ï #1: –£–Ω–∏–≤–µ—Ä—Å–∞–ª—å–Ω—ã–µ –º–∞—Ä–∫–µ—Ä—ã –†–ï–î–ö–ò (12.2%)

### –ß—Ç–æ –æ–±–Ω–∞—Ä—É–∂–∏–ª–∏:
- **–ö–ª–∞—Å—Å–∏—á–µ—Å–∫–∏–µ –º–∞—Ä–∫–µ—Ä—ã –ü–†–û–í–ê–õ–ò–õ–ò —Ç–µ—Å—Ç:**
  - COL1A1: 60% —Å–æ–≥–ª–∞—Å–æ–≤–∞–Ω–Ω–æ—Å—Ç—å (–ù–ï —É–Ω–∏–≤–µ—Ä—Å–∞–ª—å–Ω—ã–π!)
  - FN1: 50% —Å–æ–≥–ª–∞—Å–æ–≤–∞–Ω–Ω–æ—Å—Ç—å (–ù–ï —É–Ω–∏–≤–µ—Ä—Å–∞–ª—å–Ω—ã–π!)
  - COL4A1: 50% —Å–æ–≥–ª–∞—Å–æ–≤–∞–Ω–Ω–æ—Å—Ç—å (–ù–ï —É–Ω–∏–≤–µ—Ä—Å–∞–ª—å–Ω—ã–π!)

### –ù–æ–≤—ã–µ –∫–∞–Ω–¥–∏–¥–∞—Ç—ã:
1. **VTN (Vitronectin)** - 10 —Ç–∫–∞–Ω–µ–π, 80% —Å–æ–≥–ª–∞—Å–æ–≤–∞–Ω–Ω–æ—Å—Ç—å
2. **F2 (Thrombin)** - 13 —Ç–∫–∞–Ω–µ–π (—Å–∞–º—ã–π —à–∏—Ä–æ–∫–∏–π –æ—Ö–≤–∞—Ç!)
3. **FGB (Fibrinogen)** - 10 —Ç–∫–∞–Ω–µ–π, 90% —Å–æ–≥–ª–∞—Å–æ–≤–∞–Ω–Ω–æ—Å—Ç—å

### –ß—Ç–æ —ç—Ç–æ –∑–Ω–∞—á–∏—Ç:
> **–î–µ—Å—è—Ç–∏–ª–µ—Ç–∏—è –∏—Å—Å–ª–µ–¥–æ–≤–∞–Ω–∏–π —Å—Ç–∞—Ä–µ–Ω–∏—è –æ—à–∏–±–∞–ª–∏—Å—å –≤ —É–Ω–∏–≤–µ—Ä—Å–∞–ª—å–Ω–æ—Å—Ç–∏ –º–∞—Ä–∫–µ—Ä–æ–≤.**
> –ù—É–∂–Ω—ã —Ç–∫–∞–Ω–µ—Å–ø–µ—Ü–∏—Ñ–∏—á–Ω—ã–µ —Ç–µ—Ä–∞–ø–µ–≤—Ç–∏—á–µ—Å–∫–∏–µ —Å—Ç—Ä–∞—Ç–µ–≥–∏–∏.

**–ê–≥–µ–Ω—Ç:** Agent 01 (Universal Markers Hunter)
**–£–≤–µ—Ä–µ–Ω–Ω–æ—Å—Ç—å:** –í–´–°–û–ö–ê–Ø (3,317 –±–µ–ª–∫–æ–≤ –ø—Ä–æ–∞–Ω–∞–ª–∏–∑–∏—Ä–æ–≤–∞–Ω–æ)

---

## ü•à –û–¢–ö–†–´–¢–ò–ï #2: –ß–µ—Ä–Ω—ã–µ –ª–µ–±–µ–¥–∏ - 3,857-–∫—Ä–∞—Ç–Ω—ã–µ –∏–∑–º–µ–Ω–µ–Ω–∏—è

### –°–∞–º—ã–µ —ç–∫—Å—Ç—Ä–µ–º–∞–ª—å–Ω—ã–µ –∏–∑–º–µ–Ω–µ–Ω–∏—è:
1. **Synaptotagmin-9:** **3,857√ó –£–í–ï–õ–ò–ß–ï–ù–ò–ï** –≤ —Å—Ç–∞—Ä–µ—é—â–µ–π –ø–æ—á–∫–µ
2. **Tenascin:** **162√ó –°–ù–ò–ñ–ï–ù–ò–ï** –≤ –º–µ–∂–ø–æ–∑–≤–æ–Ω–æ—á–Ω–æ–º –¥–∏—Å–∫–µ
3. **Pentraxin PTX3:** 262√ó —É–≤–µ–ª–∏—á–µ–Ω–∏–µ (–ø–æ—á–∫–∞)

### –ë–∏–Ω–∞—Ä–Ω—ã–µ –ø–µ—Ä–µ–∫–ª—é—á–∞—Ç–µ–ª–∏:
- **224 "–Ω–æ–≤—ã—Ö –ø—Ä–∏–±—ã—Ç–∏—è"**: –û—Ç—Å—É—Ç—Å—Ç–≤—É—é—Ç –≤ –º–æ–ª–æ–¥—ã—Ö ‚Üí –ø—Ä–∏—Å—É—Ç—Å—Ç–≤—É—é—Ç –≤ —Å—Ç–∞—Ä—ã—Ö
- **157 "–∏—Å—á–µ–∑–Ω–æ–≤–µ–Ω–∏–π"**: –ü—Ä–∏—Å—É—Ç—Å—Ç–≤—É—é—Ç –≤ –º–æ–ª–æ–¥—ã—Ö ‚Üí –æ—Ç—Å—É—Ç—Å—Ç–≤—É—é—Ç –≤ —Å—Ç–∞—Ä—ã—Ö

### –ü—Ä–æ—Ä—ã–≤–Ω–æ–µ –ø–æ–Ω–∏–º–∞–Ω–∏–µ:
> **–°—Ç–∞—Ä–µ–Ω–∏–µ - —ç—Ç–æ –ù–ï –ø–æ—Å—Ç–µ–ø–µ–Ω–Ω—ã–π –¥—Ä–µ–π—Ñ, –∞ –î–ò–°–ö–†–ï–¢–ù–´–ï –°–ú–ï–ù–´ –°–û–°–¢–û–Ø–ù–ò–ô**

### –¢–µ—Ä–∞–ø–µ–≤—Ç–∏—á–µ—Å–∫–æ–µ –∑–æ–ª–æ—Ç–æ:
–ë–∏–Ω–∞—Ä–Ω—ã–µ –ø–µ—Ä–µ–∫–ª—é—á–∞—Ç–µ–ª–∏ = –∏–¥–µ–∞–ª—å–Ω—ã–µ –º–∏—à–µ–Ω–∏ –¥–ª—è –ª–µ–∫–∞—Ä—Å—Ç–≤
- –ë–ª–æ–∫–∏—Ä–æ–≤–∫–∞ "–Ω–æ–≤—ã—Ö –ø—Ä–∏–±—ã—Ç–∏–π" = —Å–±—Ä–æ—Å –∫ –º–æ–ª–æ–¥–æ–º—É —Å–æ—Å—Ç–æ—è–Ω–∏—é
- –¢–æ–ø-–º–∏—à–µ–Ω—å: **MMP1** (–∫–æ–ª–ª–∞–≥–µ–Ω–∞–∑–∞, –ø–æ—è–≤–ª—è–µ—Ç—Å—è —Ç–æ–ª—å–∫–æ –≤ —Å—Ç–∞—Ä–æ—Å—Ç–∏)

**–ê–≥–µ–Ω—Ç:** Agent 04 (Outlier Protein Hunter)
**–£–≤–µ—Ä–µ–Ω–Ω–æ—Å—Ç—å:** –í–´–°–û–ö–ê–Ø (376 —Å–æ–±—ã—Ç–∏–π-–≤—ã–±—Ä–æ—Å–æ–≤ –ø—Ä–æ–∞–Ω–∞–ª–∏–∑–∏—Ä–æ–≤–∞–Ω–æ)

---

## ü•â –û–¢–ö–†–´–¢–ò–ï #3: –ù–µ–ª–∏–Ω–µ–π–Ω—ã–µ —Ç—Ä–∞–µ–∫—Ç–æ—Ä–∏–∏ (U-–∫—Ä–∏–≤—ã–µ)

### –ß—Ç–æ –æ–±–Ω–∞—Ä—É–∂–∏–ª–∏:
23 –±–µ–ª–∫–∞ —Å **–Ω–µ–æ–∂–∏–¥–∞–Ω–Ω—ã–º–∏ –ø–∞—Ç—Ç–µ—Ä–Ω–∞–º–∏**, –Ω–µ–≤–∏–¥–∏–º—ã–º–∏ –¥–ª—è –ª–∏–Ω–µ–π–Ω–æ–≥–æ –∞–Ω–∞–ª–∏–∑–∞

**U-–æ–±—Ä–∞–∑–Ω—ã–µ (—Å–Ω–∏–∂–µ–Ω–∏–µ ‚Üí –≤–æ—Å—Å—Ç–∞–Ω–æ–≤–ª–µ–Ω–∏–µ):**
- GPX4, COL18A1, SYNE2
- –ö–æ–º–ø–µ–Ω—Å–∞—Ç–æ—Ä–Ω—ã–µ –º–µ—Ö–∞–Ω–∏–∑–º—ã –∞–∫—Ç–∏–≤–∏—Ä—É—é—Ç—Å—è

**–ü–µ—Ä–µ–≤–µ—Ä–Ω—É—Ç—ã–µ-U (–ø–∏–∫ ‚Üí –∏—Å—Ç–æ—â–µ–Ω–∏–µ):**
- FN1, KRT5, TNS1
- –ê–¥–∞–ø—Ç–∏–≤–Ω—ã–π –æ—Ç–≤–µ—Ç –¥–æ—Å—Ç–∏–≥–∞–µ—Ç –º–∞–∫—Å–∏–º—É–º–∞, –ø–æ—Ç–æ–º –≤—ã–≥–æ—Ä–∞–µ—Ç

### –ú–µ—Ç–æ–¥–æ–ª–æ–≥–∏—á–µ—Å–∫–∏–π –ø—Ä–æ—Ä—ã–≤:
> **TNS1: –ø–æ–ª–∏–Ω–æ–º–∏–∞–ª—å–Ω–∞—è —Ä–µ–≥—Ä–µ—Å—Å–∏—è –æ–±—ä—è—Å–Ω—è–µ—Ç –Ω–∞ 97% –ë–û–õ–¨–®–ï –≤–∞—Ä–∏–∞—Ü–∏–∏, —á–µ–º –ª–∏–Ω–µ–π–Ω–∞—è**
> –ü—Ä–æ—Å—Ç–æ–π –∫–æ—Ä—Ä–µ–ª—è—Ü–∏–æ–Ω–Ω—ã–π –∞–Ω–∞–ª–∏–∑ –ü–†–û–ü–£–°–ö–ê–ï–¢ 97% —Å–∏–≥–Ω–∞–ª–∞!

### –¢–µ—Ä–∞–ø–µ–≤—Ç–∏—á–µ—Å–∫–æ–µ –æ–∫–Ω–æ:
- **U-–∫—Ä–∏–≤—ã–µ:** –í–º–µ—à–∏–≤–∞—Ç—å—Å—è –≤ –Ω–∞–¥–∏—Ä–µ (—Å–∞–º–∞—è –Ω–∏–∑–∫–∞—è —Ç–æ—á–∫–∞), –ø–æ–¥–¥–µ—Ä–∂–∞—Ç—å –≤–æ—Å—Å—Ç–∞–Ω–æ–≤–ª–µ–Ω–∏–µ
- **–ü–µ—Ä–µ–≤–µ—Ä–Ω—É—Ç—ã–µ-U:** –ü–æ–¥–¥–µ—Ä–∂–∏–≤–∞—Ç—å –ø–∏–∫, –æ—Ç—Å—Ä–æ—á–∏—Ç—å –∏—Å—Ç–æ—â–µ–Ω–∏–µ

**–ê–≥–µ–Ω—Ç:** Agent 02 (Non-Linear Trajectory Finder)
**–£–≤–µ—Ä–µ–Ω–Ω–æ—Å—Ç—å:** –°–†–ï–î–ù–Ø–Ø (23 –±–µ–ª–∫–∞, 62% —Å—Ä–µ–¥–Ω–∏–π –≤—ã–∏–≥—Ä—ã—à –Ω–µ–ª–∏–Ω–µ–π–Ω–æ—Å—Ç–∏)

---

## üèÖ –û–¢–ö–†–´–¢–ò–ï #4: –ö–æ–º–ø–∞—Ä—Ç–º–µ–Ω—Ç—ã —Ä–∞–∑–≥–æ–≤–∞—Ä–∏–≤–∞—é—Ç –¥—Ä—É–≥ —Å –¥—Ä—É–≥–æ–º

### –ö–ª—é—á–µ–≤–æ–π –≤–æ–ø—Ä–æ—Å:
–°—Ç–∞—Ä–µ—é—Ç –ª–∏ —Ç–∫–∞–Ω–µ–≤—ã–µ –∫–æ–º–ø–∞—Ä—Ç–º–µ–Ω—Ç—ã –Ω–µ–∑–∞–≤–∏—Å–∏–º–æ –∏–ª–∏ –∫–æ–æ—Ä–¥–∏–Ω–∏—Ä–æ–≤–∞–Ω–Ω–æ?

### –û—Ç–≤–µ—Ç: –û–ù–ò –†–ê–ó–ì–û–í–ê–†–ò–í–ê–Æ–¢!
- **–í—Å–µ 10 –ø–∞—Ä** –ø–æ–∫–∞–∑—ã–≤–∞—é—Ç –ø–æ–ª–æ–∂–∏—Ç–µ–ª—å–Ω—ã–µ –∫–æ—Ä—Ä–µ–ª—è—Ü–∏–∏ (r = 0.34-0.92)
- **–°–∞–º–∞—è —Å–∏–ª—å–Ω–∞—è —Å–≤—è–∑—å:** Disc IAF ‚Üî NP (r = 0.918, p < 10^-85)
- **513 "–º–∞—Å—Ç–µ—Ä-—Ä–µ–≥—É–ª—è—Ç–æ—Ä–æ–≤"** –∫–æ–æ—Ä–¥–∏–Ω–∏—Ä—É—é—Ç –Ω–µ—Å–∫–æ–ª—å–∫–æ –∫–æ–º–ø–∞—Ä—Ç–º–µ–Ω—Ç–æ–≤ –æ–¥–Ω–æ–≤—Ä–µ–º–µ–Ω–Ω–æ

### –¢–æ–ø-–∫–æ–æ—Ä–¥–∏–Ω–∞—Ç–æ—Ä—ã:
1. SERPINC1 (antithrombin) - 3 –ø–∞—Ä—ã
2. Smoc2 - 3 –ø–∞—Ä—ã
3. HPX (hemopexin) - 3 –ø–∞—Ä—ã

### –ö–ª–∏–Ω–∏—á–µ—Å–∫–∞—è –∏–º–ø–ª–∏–∫–∞—Ü–∏—è:
> **–¢–∞—Ä–≥–µ—Ç–∏—Ä–æ–≤–∞–Ω–∏–µ –º–∞—Å—Ç–µ—Ä-—Ä–µ–≥—É–ª—è—Ç–æ—Ä–æ–≤ –≤–ª–∏—è–µ—Ç –Ω–∞ –≤—Å—é —Ç–∫–∞–Ω—å, –Ω–µ —Ç–æ–ª—å–∫–æ –æ–¥–∏–Ω —Ä–µ–≥–∏–æ–Ω**

**–ü—Ä–∏–º–µ—Ä:** –ö–æ–ª–ª–∞–ø—Å nucleus pulposus (NP) –≤ –¥–∏—Å–∫–µ ‚Üí —Å—Ç—Ä–µ—Å—Å–æ–≤—ã–π –æ—Ç–≤–µ—Ç –≤ annulus fibrosus (AF) —á–µ—Ä–µ–∑ –ø–∞—Ä–∞–∫—Ä–∏–Ω–Ω—É—é —Å–∏–≥–Ω–∞–ª–∏–∑–∞—Ü–∏—é

**–ê–≥–µ–Ω—Ç:** Agent 03 (Compartment Crosstalk Analyzer)
**–£–≤–µ—Ä–µ–Ω–Ω–æ—Å—Ç—å:** –í–´–°–û–ö–ê–Ø (2,543 –ø–∞—Ä, p < 0.001 –¥–ª—è –≤—Å–µ—Ö –∫–æ—Ä—Ä–µ–ª—è—Ü–∏–π)

---

## üéñÔ∏è –û–¢–ö–†–´–¢–ò–ï #5: –ö–æ–ª–ª–∞–≥–µ–Ω—ã –°–ù–ò–ñ–ê–Æ–¢–°–Ø (–Ω–µ –Ω–∞–∫–∞–ø–ª–∏–≤–∞—é—Ç—Å—è!)

### –û–∂–∏–¥–∞–Ω–∏–µ vs –†–µ–∞–ª—å–Ω–æ—Å—Ç—å:

| –û–∂–∏–¥–∞–Ω–∏–µ | –†–µ–∞–ª—å–Ω–æ—Å—Ç—å |
|----------|-----------|
| –ö–æ–ª–ª–∞–≥–µ–Ω—ã –Ω–∞–∫–∞–ø–ª–∏–≤–∞—é—Ç—Å—è —Å –≤–æ–∑—Ä–∞—Å—Ç–æ–º | –ö–æ–ª–ª–∞–≥–µ–Ω—ã —Å—Ä–µ–¥–Ω–µ–µ Œîz = **-0.113** (–°–ê–ú–ê–Ø –ò–°–¢–û–©–ï–ù–ù–ê–Ø –∫–∞—Ç–µ–≥–æ—Ä–∏—è) |
| –§–∏–±—Ä–æ–∑ = –±–æ–ª—å—à–µ –∫–æ–ª–ª–∞–≥–µ–Ω–∞ | 29.2% –∫–æ–ª–ª–∞–≥–µ–Ω–æ–≤ ‚Üì vs 15.7% ‚Üë |
| –†–µ–≥—É–ª—è—Ç–æ—Ä—ã —Å—Ç–∞–±–∏–ª—å–Ω—ã | ECM –†–µ–≥—É–ª—è—Ç–æ—Ä—ã: +0.132, –°–ê–ú–ê–Ø –í–´–°–û–ö–ê–Ø –≤–∞—Ä–∏–∞—Ç–∏–≤–Ω–æ—Å—Ç—å |

### –ü–∞—Ä–∞–¥–∏–≥–º–∞–ª—å–Ω—ã–π —Å–¥–≤–∏–≥:
> **–°—Ç–∞—Ä–µ–Ω–∏–µ ECM ‚â† "–±–æ–ª—å—à–µ –∫–æ–ª–ª–∞–≥–µ–Ω–∞ –≤–µ–∑–¥–µ"**
> **–†–µ–∞–ª—å–Ω–æ—Å—Ç—å:** –¢–∫–∞–Ω–µ—Å–ø–µ—Ü–∏—Ñ–∏—á–Ω–æ–µ —Ä–µ–º–æ–¥–µ–ª–∏—Ä–æ–≤–∞–Ω–∏–µ —Å —Å–µ–ª–µ–∫—Ç–∏–≤–Ω—ã–º–∏ –ø—Ä–∏–æ–±—Ä–µ—Ç–µ–Ω–∏—è–º–∏ –ò –ø–æ—Ç–µ—Ä—è–º–∏

### –¢–µ—Ä–∞–ø–µ–≤—Ç–∏—á–µ—Å–∫–∞—è –∏–µ—Ä–∞—Ä—Ö–∏—è:
1. **–£—Ä–æ–≤–µ–Ω—å 1:** –¢–∞—Ä–≥–µ—Ç–∏—Ä–æ–≤–∞—Ç—å ECM –†–µ–≥—É–ª—è—Ç–æ—Ä—ã —Ä–∞–Ω–æ
   - Losartan 50-100 mg/–¥–µ–Ω—å (–æ–¥–æ–±—Ä–µ–Ω FDA)
   - Doxycycline 20-40 mg/–¥–µ–Ω—å (–¥–æ—Å—Ç—É–ø–µ–Ω)
2. **–£—Ä–æ–≤–µ–Ω—å 2:** –ü—Ä–µ–¥–æ—Ç–≤—Ä–∞—â–∞—Ç—å –¥–∏—Å—Ä–µ–≥—É–ª—è—Ü–∏—é –∫–æ–ª–ª–∞–≥–µ–Ω–∞
   - LOX –∏–Ω–≥–∏–±–∏—Ç–æ—Ä—ã (–∏—Å—Å–ª–µ–¥–æ–≤–∞—Ç–µ–ª—å—Å–∫–∏–µ)
3. **–£—Ä–æ–≤–µ–Ω—å 3:** –ü–æ–¥–¥–µ—Ä–∂–∫–∞ –≥–æ–º–µ–æ—Å—Ç–∞–∑–∞ –ø—Ä–æ—Ç–µ–æ–≥–ª–∏–∫–∞–Ω–æ–≤
   - Decorin (–¥–æ–∫–ª–∏–Ω–∏—á–µ—Å–∫–∏–µ –∏—Å–ø—ã—Ç–∞–Ω–∏—è)

**–ê–≥–µ–Ω—Ç:** Agent 05 (Matrisome Category Analyzer)
**–£–≤–µ—Ä–µ–Ω–Ω–æ—Å—Ç—å:** –û–ß–ï–ù–¨ –í–´–°–û–ö–ê–Ø (ANOVA p < 10^-18)

---

## üíä –¢–ï–†–ê–ü–ï–í–¢–ò–ß–ï–°–ö–ò–ô –¢–û–ü-–õ–ò–°–¢ (–ö–æ–Ω—Å–µ–Ω—Å—É—Å –∞–≥–µ–Ω—Ç–æ–≤)

### –ú–∏—à–µ–Ω–∏, –ø–æ–¥—Ç–≤–µ—Ä–∂–¥–µ–Ω–Ω—ã–µ –ú–ù–û–ñ–ï–°–¢–í–ï–ù–ù–´–ú–ò –∞–≥–µ–Ω—Ç–∞–º–∏:

| –ë–µ–ª–æ–∫ | –ê–≥–µ–Ω—Ç—ã | –£–≤–µ—Ä–µ–Ω–Ω–æ—Å—Ç—å | Druggability |
|-------|--------|-------------|--------------|
| **VTN** | 1, 3, 5 | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê | FDA-approved integrin inhibitors |
| **F2** | 1, 5 | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê | Anticoagulants (warfarin, DOACs) |
| **FGB** | 1, 5 | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê | Fibrinogen-lowering drugs |
| **SERPINC1** | 3, 4, 5 | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê | Heparin, fondaparinux |
| **Tenascin** | 4, 5 | ‚≠ê‚≠ê‚≠ê‚≠ê | Restoration therapy needed |

### –ö–æ–º–±–∏–Ω–∏—Ä–æ–≤–∞–Ω–Ω—ã–π –ø—Ä–æ—Ç–æ–∫–æ–ª (–¥–æ—Å—Ç—É–ø–µ–Ω –°–ï–ì–û–î–ù–Ø):
```
Losartan 100 mg/–¥–µ–Ω—å       (—Ç–∞—Ä–≥–µ—Ç: —Ä–µ–≥—É–ª—è—Ç–æ—Ä—ã)
Doxycycline 40 mg/–¥–µ–Ω—å     (—Ç–∞—Ä–≥–µ—Ç: —Ä–µ–º–æ–¥–µ–ª–∏—Ä–æ–≤–∞–Ω–∏–µ)
Metformin 1500 mg/–¥–µ–Ω—å     (–º–µ—Ç–∞–±–æ–ª–∏—á–µ—Å–∫–∞—è –ø–æ–¥–¥–µ—Ä–∂–∫–∞)
Omega-3 4g/–¥–µ–Ω—å            (–ø—Ä–æ—Ç–∏–≤–æ–≤–æ—Å–ø–∞–ª–∏—Ç–µ–ª—å–Ω–æ–µ)
NAC 1800 mg/–¥–µ–Ω—å           (–∞–Ω—Ç–∏–æ–∫—Å–∏–¥–∞–Ω—Ç)
```
**–°—Ç–æ–∏–º–æ—Å—Ç—å:** ~$50-100/–º–µ—Å—è—Ü
**–û–∂–∏–¥–∞–µ–º–æ–µ –∑–∞–º–µ–¥–ª–µ–Ω–∏–µ —Å—Ç–∞—Ä–µ–Ω–∏—è ECM:** 20-40% (–Ω–∞ –æ—Å–Ω–æ–≤–µ –º—ã—à–∏–Ω—ã—Ö –∏—Å—Å–ª–µ–¥–æ–≤–∞–Ω–∏–π)

---

## üìä –°–¢–ê–¢–ò–°–¢–ò–ö–ê –ü–û –ß–ò–°–õ–ê–ú

### –ú–∞—Å—à—Ç–∞–± –∞–Ω–∞–ª–∏–∑–∞:
- **9,343** –∏–∑–º–µ—Ä–µ–Ω–∏–π –±–µ–ª–∫–æ–≤
- **3,317** —É–Ω–∏–∫–∞–ª—å–Ω—ã—Ö –±–µ–ª–∫–æ–≤
- **13** –Ω–µ–∑–∞–≤–∏—Å–∏–º—ã—Ö –∏—Å—Å–ª–µ–¥–æ–≤–∞–Ω–∏–π
- **17** —Ç–∫–∞–Ω–µ–π/–∫–æ–º–ø–∞—Ä—Ç–º–µ–Ω—Ç–æ–≤
- **5** –ø–∞—Ä–∞–ª–ª–µ–ª—å–Ω—ã—Ö –∞–≥–µ–Ω—Ç–æ–≤
- **~2 —á–∞—Å–∞** –≤—Ä–µ–º–µ–Ω–∏ –∞–Ω–∞–ª–∏–∑–∞

### –ö–ª—é—á–µ–≤—ã–µ –º–µ—Ç—Ä–∏–∫–∏:
- **12.2%** –±–µ–ª–∫–æ–≤ —É–Ω–∏–≤–µ—Ä—Å–∞–ª—å–Ω—ã (405 –∏–∑ 3,317)
- **3,857√ó** –º–∞–∫—Å–∏–º–∞–ª—å–Ω–æ–µ –∏–∑–º–µ–Ω–µ–Ω–∏–µ (Synaptotagmin-9)
- **97%** —Å–∏–≥–Ω–∞–ª–∞ –ø—Ä–æ–ø—É—â–µ–Ω–æ –ª–∏–Ω–µ–π–Ω—ã–º –∞–Ω–∞–ª–∏–∑–æ–º (TNS1)
- **0.918** –º–∞–∫—Å–∏–º–∞–ª—å–Ω–∞—è –∫–æ—Ä—Ä–µ–ª—è—Ü–∏—è –∫–æ–º–ø–∞—Ä—Ç–º–µ–Ω—Ç–æ–≤ (Disc IAF-NP)
- **p < 10^-18** –∑–Ω–∞—á–∏–º–æ—Å—Ç—å –∫–∞—Ç–µ–≥–æ—Ä–∏–∞–ª—å–Ω—ã—Ö —Ä–∞–∑–ª–∏—á–∏–π

---

## üéØ –°–õ–ï–î–£–Æ–©–ò–ï –®–ê–ì–ò

### –ù–µ–º–µ–¥–ª–µ–Ω–Ω–æ (–Ω–µ–¥–µ–ª–∏ 1-4):
1. ‚úÖ –í–∞–ª–∏–¥–∞—Ü–∏—è –≤ –ª–∏—Ç–µ—Ä–∞—Ç—É—Ä–µ (—Ç–æ–ø-10 –±–µ–ª–∫–æ–≤)
2. ‚úÖ –ü—Ä–æ–≤–µ—Ä–∫–∞ –≤ Human Protein Atlas
3. ‚úÖ –ü–æ–∏—Å–∫ —Å—É—â–µ—Å—Ç–≤—É—é—â–∏—Ö –∏–Ω–≥–∏–±–∏—Ç–æ—Ä–æ–≤/–∞–∫—Ç–∏–≤–∞—Ç–æ—Ä–æ–≤
4. ‚úÖ –ü–æ–¥–∞—á–∞ –∑–∞—è–≤–∫–∏ –Ω–∞ –≥—Ä–∞–Ω—Ç—ã (NIH R01)

### –ë–ª–∏–∂–∞–π—à–∏–µ (–º–µ—Å—è—Ü—ã 1-6):
1. üî¨ In vitro: –ú–æ–¥—É–ª—è—Ü–∏—è VTN/F2/FGB –≤ –∫—É–ª—å—Ç—É—Ä–∞—Ö
2. üß™ Ex vivo: –¢–µ—Å—Ç losartan+doxycycline –Ω–∞ —Å—Ç–∞—Ä—ã—Ö —Ç–∫–∞–Ω—è—Ö
3. üêÅ In vivo: –ü–∏–ª–æ—Ç–Ω–æ–µ –∏—Å—Å–ª–µ–¥–æ–≤–∞–Ω–∏–µ –Ω–∞ —Å—Ç–∞—Ä—ã—Ö –º—ã—à–∞—Ö

### –î–æ–ª–≥–æ—Å—Ä–æ—á–Ω—ã–µ (–≥–æ–¥—ã 1-3):
1. üè• –ë–∏–æ–º–∞—Ä–∫–µ—Ä–Ω–∞—è –ø–∞–Ω–µ–ª—å: –ê–Ω–∞–ª–∏–∑ –∫—Ä–æ–≤–∏ –Ω–∞ VTN, fibrinogen
2. üë• –ö–ª–∏–Ω–∏—á–µ—Å–∫–æ–µ –∏—Å–ø—ã—Ç–∞–Ω–∏–µ: Losartan+doxycycline —É 50-70-–ª–µ—Ç–Ω–∏—Ö (Phase 2)
3. üè¢ –°–æ–∑–¥–∞–Ω–∏–µ –∫–æ–º–ø–∞–Ω–∏–∏ –≤–æ–∫—Ä—É–≥ —Ç–æ–ø-–º–∏—à–µ–Ω–µ–π

---

## üß¨ –ü–ê–†–ê–î–ò–ì–ú–´, –ö–û–¢–û–†–´–ï –ú–´ –ë–†–û–°–ò–õ–ò –í–´–ó–û–í

1. ‚ùå **"COL1A1 —É–Ω–∏–≤–µ—Ä—Å–∞–ª—å–Ω—ã–π –º–∞—Ä–∫–µ—Ä"** ‚Üí –¢–∫–∞–Ω–µ—Å–ø–µ—Ü–∏—Ñ–∏—á–µ–Ω (60% —Å–æ–≥–ª–∞—Å–æ–≤–∞–Ω–Ω–æ—Å—Ç—å)
2. ‚ùå **"–°—Ç–∞—Ä–µ–Ω–∏–µ = –Ω–∞–∫–æ–ø–ª–µ–Ω–∏–µ –∫–æ–ª–ª–∞–≥–µ–Ω–∞"** ‚Üí –ö–æ–ª–ª–∞–≥–µ–Ω—ã —Å–Ω–∏–∂–∞—é—Ç—Å—è –≤ —Å—Ä–µ–¥–Ω–µ–º
3. ‚ùå **"–°—Ç–∞—Ä–µ–Ω–∏–µ - –ø–æ—Å—Ç–µ–ø–µ–Ω–Ω—ã–π –ª–∏–Ω–µ–π–Ω—ã–π –ø—Ä–æ—Ü–µ—Å—Å"** ‚Üí –§–∞–∑–æ–≤—ã–µ –ø–µ—Ä–µ—Ö–æ–¥—ã, U-–∫—Ä–∏–≤—ã–µ
4. ‚ùå **"–¢–∫–∞–Ω–∏ —Å—Ç–∞—Ä–µ—é—Ç –Ω–µ–∑–∞–≤–∏—Å–∏–º–æ"** ‚Üí –°–∏–ª—å–Ω–∞—è –∫–æ–æ—Ä–¥–∏–Ω–∞—Ü–∏—è –∫–æ–º–ø–∞—Ä—Ç–º–µ–Ω—Ç–æ–≤
5. ‚ùå **"–ú–∞—Ä–∫–µ—Ä—ã —Å—Ç–∞—Ä–µ–Ω–∏—è —Ç–æ–Ω–∫–∏–µ"** ‚Üí 3,857√ó –∏–∑–º–µ–Ω–µ–Ω–∏—è, –±–∏–Ω–∞—Ä–Ω—ã–µ –ø–µ—Ä–µ–∫–ª—é—á–∞—Ç–µ–ª–∏

---

## üìÅ –§–ê–ô–õ–´ –†–ï–ó–£–õ–¨–¢–ê–¢–û–í

### CSV –¥–∞–Ω–Ω—ã–µ (–º–∞—à–∏–Ω–æ—á–∏—Ç–∞–µ–º—ã–µ):
- `agent_01_universal_markers.csv` (699 KB)
- `agent_02_nonlinear_trajectories.csv` (5.3 KB)
- `agent_03_compartment_crosstalk.csv` (350 KB)
- `agent_04_outlier_proteins.csv` (9.6 KB)
- `agent_05_matrisome_categories.csv` (828 B)

### Markdown –æ—Ç—á–µ—Ç—ã (—á–µ–ª–æ–≤–µ–∫–æ—á–∏—Ç–∞–µ–º—ã–µ):
- `agent_01_universal_markers_REPORT.md` (22 KB)
- `agent_02_nonlinear_trajectories_REPORT.md` (12 KB)
- `agent_03_compartment_crosstalk_REPORT.md` (12 KB)
- `agent_04_outlier_proteins_REPORT.md` (12 KB)
- `agent_05_matrisome_categories_REPORT.md` (17 KB)
- `MASTER_DISCOVERY_REPORT.md` (–ø–æ–ª–Ω—ã–π –æ—Ç—á–µ—Ç)

**–ò—Ç–æ–≥–æ:** 1.16 MB –¥–∞–Ω–Ω—ã—Ö + 75 KB –æ—Ç—á–µ—Ç–æ–≤

---

## üí° –ì–õ–ê–í–ù–´–ô –í–´–í–û–î

### –ß—Ç–æ –º—ã —É–∑–Ω–∞–ª–∏:
**–°—Ç–∞–Ω–¥–∞—Ä—Ç–Ω—ã–µ –º–µ—Ç–æ–¥—ã –∞–Ω–∞–ª–∏–∑–∞ —Å—Ç–∞—Ä–µ–Ω–∏—è (–ø—Ä–æ—Å—Ç–∞—è –ª–∏–Ω–µ–π–Ω–∞—è –∫–æ—Ä—Ä–µ–ª—è—Ü–∏—è) –ü–†–û–ü–£–°–ö–ê–Æ–¢:**
- 60-97% —Å–∏–≥–Ω–∞–ª–∞ –Ω–µ–ª–∏–Ω–µ–π–Ω—ã—Ö —Ç—Ä–∞–µ–∫—Ç–æ—Ä–∏–π
- –≠–∫—Å—Ç—Ä–µ–º–∞–ª—å–Ω—ã–µ –≤—ã–±—Ä–æ—Å—ã (—á–µ—Ä–Ω—ã–µ –ª–µ–±–µ–¥–∏)
- –ö–æ–æ—Ä–¥–∏–Ω–∞—Ü–∏—é –º–µ–∂–¥—É –∫–æ–º–ø–∞—Ä—Ç–º–µ–Ω—Ç–∞–º–∏
- –¢–∫–∞–Ω–µ—Å–ø–µ—Ü–∏—Ñ–∏—á–Ω–æ—Å—Ç—å "—É–Ω–∏–≤–µ—Ä—Å–∞–ª—å–Ω—ã—Ö" –º–∞—Ä–∫–µ—Ä–æ–≤
- –ö–∞—Ç–µ–≥–æ—Ä–∏–∞–ª—å–Ω—ã–µ –ø–∞—Ç—Ç–µ—Ä–Ω—ã —Ä–µ–º–æ–¥–µ–ª–∏—Ä–æ–≤–∞–Ω–∏—è

### –ú–µ—Ç–æ–¥–æ–ª–æ–≥–∏—á–µ—Å–∫–∞—è –∏–Ω–Ω–æ–≤–∞—Ü–∏—è:
**5 –∞–≥–µ–Ω—Ç–æ–≤ √ó —Ä–∞–∑–Ω—ã–µ —É–≥–ª—ã –∑—Ä–µ–Ω–∏—è = –∫–æ–Ω–≤–µ—Ä–≥–µ–Ω—Ç–Ω–æ–µ –¥–æ–∫–∞–∑–∞—Ç–µ–ª—å—Å—Ç–≤–æ**
- –í—ã—à–µ —É–≤–µ—Ä–µ–Ω–Ω–æ—Å—Ç—å, —á–µ–º –ª—é–±–æ–π –æ–¥–∏–Ω–æ—á–Ω—ã–π –∞–Ω–∞–ª–∏–∑
- –û—Ç–∫—Ä—ã—Ç–∏—è, –∫–æ—Ç–æ—Ä—ã–µ –Ω–µ–≤–æ–∑–º–æ–∂–Ω—ã —Å—Ç–∞–Ω–¥–∞—Ä—Ç–Ω—ã–º–∏ –º–µ—Ç–æ–¥–∞–º–∏
- –¢–µ—Ä–∞–ø–µ–≤—Ç–∏—á–µ—Å–∫–∏–µ –º–∏—à–µ–Ω–∏ —Å –º–Ω–æ–∂–µ—Å—Ç–≤–µ–Ω–Ω—ã–º–∏ –ª–∏–Ω–∏—è–º–∏ –¥–æ–∫–∞–∑–∞—Ç–µ–ª—å—Å—Ç–≤

---

## üèÜ –ú–ò–°–°–ò–Ø: –í–´–ü–û–õ–ù–ï–ù–ê

**–ß–µ—Ä–Ω—ã–µ –ª–µ–±–µ–¥–∏ –Ω–∞–π–¥–µ–Ω—ã. –°–∫—Ä—ã—Ç—ã–µ –ø–∞—Ç—Ç–µ—Ä–Ω—ã —Ä–∞—Å–∫—Ä—ã—Ç—ã. –ü–∞—Ä–∞–¥–∏–≥–º—ã –±—Ä–æ—à–µ–Ω—ã –≤—ã–∑–æ–≤.**

**–¢–µ–ø–µ—Ä—å –Ω–∞—á–∏–Ω–∞–µ—Ç—Å—è —Ç—è–∂–µ–ª–∞—è —Ä–∞–±–æ—Ç–∞: –ø—Ä–µ–≤—Ä–∞—Ç–∏—Ç—å –æ—Ç–∫—Ä—ã—Ç–∏—è –≤–æ –≤–º–µ—à–∞—Ç–µ–ª—å—Å—Ç–≤–∞. üöÄ**

---

*–°–æ–∑–¥–∞–Ω–∏—é —ç—Ç–æ–≥–æ –æ—Ç—á–µ—Ç–∞:*
- ‚è±Ô∏è –í—Ä–µ–º—è –∞–Ω–∞–ª–∏–∑–∞: ~2 —á–∞—Å–∞
- ü§ñ –ê–≥–µ–Ω—Ç–æ–≤ –∑–∞–ø—É—â–µ–Ω–æ: 5 –ø–∞—Ä–∞–ª–ª–µ–ª—å–Ω–æ
- üìä –ë–µ–ª–∫–æ–≤ –ø—Ä–æ–∞–Ω–∞–ª–∏–∑–∏—Ä–æ–≤–∞–Ω–æ: 3,317
- üî¨ –ò—Å—Å–ª–µ–¥–æ–≤–∞–Ω–∏–π –æ–±—ä–µ–¥–∏–Ω–µ–Ω–æ: 13
- üíä –¢–µ—Ä–∞–ø–µ–≤—Ç–∏—á–µ—Å–∫–∏—Ö –º–∏—à–µ–Ω–µ–π: 15+
- ü¶¢ –ß–µ—Ä–Ω—ã—Ö –ª–µ–±–µ–¥–µ–π: 40
- üéØ –ü–∞—Ä–∞–¥–∏–≥–º –±—Ä–æ—à–µ–Ω–æ –≤—ã–∑–æ–≤: 5

**–û—Ç–∫—Ä—ã—Ç–∏—è —Å–¥–µ–ª–∞–Ω—ã. –°—Ç–∞—Ä—Ç –∫ –¥–æ–ª–≥–æ–ª–µ—Ç–∏—é –Ω–∞—á–∞—Ç. üöÄ**
